Read by QxMD icon Read

Cardiovascular Therapeutics

Wei Gong, Youcai Ma, Aobo Li, Shi Han, Shaoping Nie
BACKGROUND/AIMS: Cardiac rupture (CR) is a catastrophic complication of acute myocardial infarction (MI). At present, there are no effective pharmacological strategies for preventing post-MI rupture. Here we investigated the effect of trimetazidine (TMZ) on post-MI CR. METHODS: MI models were induced by left coronary artery ligation in male C57BL/6 mice. Animals allocated to the rupture incidence were closely monitored for 7 days; autopsy was performed once animals were found dead to determine the reason of death...
July 17, 2018: Cardiovascular Therapeutics
Anna Jonsson, Helena Norberg, Ellinor Bergdahl, Krister Lindmark
AIM: Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aims to investigate why MRA is not used to full extent. METHODS: A complete community based heart failure population was studied. Several variables were collected and medical records were scrutinized to identify reasons for not prescribing MRA. RESULTS: Of 2029 patients, 812 had EF ≤ 40%...
July 17, 2018: Cardiovascular Therapeutics
Luca Zanella, Giacomo Zoppellaro, Lucia Marigo, Gentian Denas, Seena Padayattil Jose, Vittorio Pengo
BACKGROUND: Intracranial haemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE: Search for individual risk factors and bleeding risk scores (HAS-BLED, ATRIA and ORBIT) associated with ICHs in patients with atrial fibrillation treated with VKAs. METHODS: This is a retrospective case-control study in a single Thrombosis Centre...
July 14, 2018: Cardiovascular Therapeutics
Zhen Ge, Michela Faggioni, Usman Baber, Samantha Sartori, Sabato Sorrentino, Serdar Farhan, Jaya Chandrasekhar, Birgit Vogel, Abdul Qadeer, Jonathan Halperin, Vivek Reddy, Srinivas Dukkipati, George Dangas, Roxana Mehran
AIMS: Catheter ablation for atrial fibrillation (AF) is associated with a transitory increase in the risk of both thromboembolic and bleeding events. Evidence on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients undergoing AF ablation mostly comes from small observational studies, underpowered to detect differences in clinical outcomes between NOACs and VKAs treated patients. This updated meta-analysis aimed to determine the safety and efficacy of periprocedural anticoagulation with NOACs compared with vitamin K antagonists (VKAs) in AF patients undergoing catheter ablation...
July 3, 2018: Cardiovascular Therapeutics
Vasilios G Athyros, Niki Katsiki, Dimitri P Mikhailidis
No abstract text is available yet for this article.
June 8, 2018: Cardiovascular Therapeutics
Monica Teng, Ying Jiao Zhao, Ai Leng Khoo, Rajiv Ananthakrishna, Tiong Cheng Yeo, Boon Peng Lim, Mark Y Chan, Joshua P Loh
AIM: Compared with second-generation durable polymer drug-eluting stents (DP-DES), the cost-effectiveness of biodegradable polymer drug-eluting stents (BP-DES) remains unclear in the real-world setting. We assessed the cost-effectiveness of BP-DES in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). METHODS: We developed a decision-analytic model to compare the cost-effectiveness of BP-DES to DP-DES over 1 year and 5 years from healthcare payer perspective...
June 5, 2018: Cardiovascular Therapeutics
Yaling Han, Jiyan Chen, Miaohan Qiu, Yi Li, Jing Li, Yingqing Feng, Jian Qiu, Liang Meng, Yihong Sun, Guizhou Tao, Zhaohui Wu, Chunyu Yang, Jincheng Guo, Kui Pu, Shaoliang Chen, Xiaozeng Wang
BACKGROUND: The prognosis of patients with coronary artery disease (CAD) at hospital discharge was constantly varying, and postdischarge risk of ischemic events remain a concern. However, risk prediction tools to identify risk of ischemia for these patients has not yet been reported. AIMS: We sought to develop a scoring system for predicting long-term ischemic events in CAD patients receiving antiplatelet therapy that would be beneficial in appropriate personalized decision-making for these patients...
June 5, 2018: Cardiovascular Therapeutics
Barak Zafrir, Ayman Jubran
AIM: PCSK9 inhibitors (PCSK9i) effectively lower cholesterol levels in randomized trials with reduction in cardiovascular outcomes and favorable safety profile. However, the access to PCSK9i is limited due to high cost and data regarding the use of PCSK9i in real-world practice is limited. METHODS: Data on all patients submitted for approval of PCSK9i at a regional lipid clinic, outside of clinical trials. Patients' profile, approval rates, low-density lipoprotein cholesterol (LDL-C) reduction rates, and adverse events were evaluated...
June 4, 2018: Cardiovascular Therapeutics
Pei Zhu, Xiaofang Tang, Jingjing Xu, Ying Song, Ru Liu, Yin Zhang, Lijian Gao, Zhan Gao, Jue Chen, Yuejin Yang, Runlin Gao, Bo Xu, Jinqing Yuan
AIM: To evaluate the incidence, predictors and outcomes of post-discharge gastrointestinal bleeding (GIB) in patients underwent percutaneous coronary intervention (PCI) in a 2-year follow-up study. METHODS AND RESULTS: All consecutive patients who underwent PCI throughout 2013 were enrolled. Multivariable cox proportional hazards regression were used to identify predictors of post-discharge GIB and two year major adverse cardiovascular and cerebrovascular events (MACCE)...
June 4, 2018: Cardiovascular Therapeutics
Marcello Rattazzi, Elisabetta Faggin, Elisa Bertacco, Chiara Nardin, Leopoldo Pagliani, Mario Plebani, Francesco Cinetto, Diego Guidolin, Massimo Puato, Paolo Pauletto
INTRODUCTION: Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification. AIMS: To compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice...
May 30, 2018: Cardiovascular Therapeutics
Ningning Tang, Shaoyan Jiang, Yanyan Yang, Shaoyan Liu, Murugavel Ponnusamy, Hui Xin, Tao Yu
Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages play a crucial role in the occurrence and development of this disease. The regulation and stabilization of these cells are a key therapeutic strategy for DM-associated atherosclerosis. An increasing number of evidences implicate that various types of noncoding RNAs (ncRNAs) play a vital role in many cellular responses as well as in physiological and pathological processes of atherosclerosis and DM that drive atherogenic/antiatherogenic processes in those cells...
May 24, 2018: Cardiovascular Therapeutics
Zhengqin Zhai, Shuang Zhao, Min Tang, Liujun Jia, Shu Zhang
AIM: Median nerve stimulation (MNS) is a novel neuromodulation approach for treatment of ventricular arrhythmia, but little is known about its chronic effects. The aim of this study was to investigate the effects of chronic MNS on ventricular arrhythmia and ventricular dysfunction postmyocardial infarction (MI). METHOD: Two weeks after MI, 12 rabbits were randomly divided into control and MNS groups, and chronic MNS was performed in MNS group for 2 weeks. Ventricular function and arrhythmias; sympathetic innervation and activity; and interleukin-1 β (IL-1 β) and norepinephrine (NE) levels were analyzed...
May 24, 2018: Cardiovascular Therapeutics
Pieter Martens, Hanne Beliën, Matthias Dupont, Pieter Vandervoort, Wilfried Mullens
BACKGROUND: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. METHODS: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker])...
May 17, 2018: Cardiovascular Therapeutics
Bruna Eibel, Melissa Kristochek, Thiago R Peres, Lucinara D Dias, Daniela R Dartora, Karina R Casali, Renato A K Kalil, Alexandre M Lehnen, Maria Claudia Irigoyen, Melissa M Markoski
AIM: To examine the interference of β-blockers with the chemokine stromal cell-derived factor-1 (SDF-1) found in cell homing receptors, C-X-C chemokine receptor type 4 (CXCR-4) and CXCR-7, and regulatory proteins of homing pathways, we administered atenolol, carvedilol, metoprolol, and propranolol for 30 days using an orogastric tube to hypertensive rats. METHOD: We collected blood samples before and after treatment and quantified the levels of SDF-1 with enzyme-linked immunosorbent assay (ELISA)...
May 12, 2018: Cardiovascular Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
August 2018: Cardiovascular Therapeutics
Manal M Alem
AIM: Oxidative stress and endothelial dysfunction are two inter-related conditions commonly seen in patients with cardiovascular risk factors. The enzyme, xanthine oxidase, is an important contributor to these phenomena but to a variable degree in different patient populations. This meta-analysis will summarize the effect of allopurinol, an established xanthine oxidase inhibitor, on endothelial function among patients with different comorbidities. METHODS: Medline Complete, PubMed, ProQuest, ClinicalKey, Wiley Online Library, and Cochrane Central Register of Controlled Trials were searched till July 29, 2017...
August 2018: Cardiovascular Therapeutics
Manolis Vavuranakis, Maria Kariori, Lilly Scott, Konstantinos Kalogeras, Gerasimos Siasos, Dimitrios Vrachatis, Maria Lavda, Charalampos Kalantzis, Michael Vavuranakis, Evangelia Bei, Carmen-Maria Moldovan, Evangelos Oikonomou, Christodoulos Stefanadis, Dimitrios Tousoulis
AIM: High position of the self-expandable bioprosthesis CoreValve/Evolut R has been proved to affect immediate hemodynamics of the valve. Whether this may have any impact on long-term procedural outcome has not been defined yet. The purpose of this study was to assess whether the final position of aortic bioprosthesis affects its long-term functionality. METHOD: Consecutive patients (pts) who underwent successful TAVI procedure were evaluated and separated into 2 groups according to the implantation depth (ID): Group I: pts with 4 mm <ID ≤13 mm; Group II: pts with ID ≤4 mm...
June 2018: Cardiovascular Therapeutics
Chun Yang, Houda Tahiri, Chenrongrong Cai, Muqing Gu, Carmen Gagnon, Pierre Hardy
AIM: Excess angiogenesis or neovascularization plays a key role in the pathophysiology of several ocular diseases such as retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration. microRNA-181a (miR-181a) was found highly expressed in retina and choroidal tissues. This study intends to investigate the role of miR-181a in the regulation of ocular neovascularization in different pathophysiological conditions. METHOD: We performed the RNA sequence to identify the microRNAs components of anti-angiogenic lymphocyte-derived microparticles (LMPs)...
June 2018: Cardiovascular Therapeutics
Lovedeep Singh, Jasleen K Virdi, Leonid N Maslov, Nirmal Singh, Amteshwar S Jaggi
BACKGROUND: Adenosine is a breakdown product of adenosine triphosphate and plays an important role in pharmacological preconditioning. The cardioprotective effects of adenosine preconditioning are well established. However, the possible mechanisms need to be explored. AIM: This study was aimed to investigate the possible mechanisms involved in adenosine preconditioning-induced cardioprotection in rats. METHODS: Rat heart was isolated and perfused on Langendorff apparatus...
June 2018: Cardiovascular Therapeutics
Kai Xu, Yaling Han, Bo Xu, Yuejin Yang, Geng Wang, Hui Li, Yong Sun, Ling Tao, Haichang Wang, Zuyi Yuan, Huiliang Liu, Jinghua Liu, Yongping Jia, Genshan Ma, Guosheng Fu, Xiaodong Li, Shuren Li, Shouli Wang, Kui Pu
AIMS: We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS: Patients (n = 419) scheduled to undergo percutaneous coronary intervention (PCI) were randomized to receive either the EXCEL 2 stent (n = 208) or the EXCEL stent (n = 211) from 15 Chinese centers. At 9 months, primary endpoint in-stent late loss (LL) difference was -0...
June 2018: Cardiovascular Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"